fashion -WSS

fashion

author：fashion 2025-09-29 23:12:39 - browse：549

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — Illustration: Alex Hogan/STAT; Photo: Eisai via AP

Seven months after US drug regulators fully approved Biogen’s treatment for Alzheimer’s disease, only about 2,000 patients are taking the medicine nationwide, the company said Tuesday.

Biogen’s chief executive, Christopher A. Viehbacher, said as the firm released fourth-quarter earnings that he had expected the slow uptake and sees considerable demand for the medication. He told reporters that 3,800 patients with early-stage Alzheimer’s have signed up on multiple registries to receive the drug, called Leqembi, as of last month.

Before patients can get the drug, which costs $26,500-a-year, they must undergo a brain scan or a spinal tap to confirm that they have build-up of deposits of a sticky toxic protein called beta-amyloid that is a hallmark of the disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Bird flu researchers hone in on Finland’s mink farms

focus

WSS

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

Health AI: on the border between health care and tech

What to know about the judge who will handle the Trump case

Health AI: on the border between health care and tech

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

Megan Rapinoe shares emotional post following US Women's World Cup exit

hotspot

fashion

focus

Continuity nursing helped my family in our darkest PICU moments

Supreme Court wrestles with OxyContin maker's bankruptcy deal

United colonoscopy coverage change 'may cost lives,' doctors say

Idaho college killings prosecutors challenge defense's grand jury claims

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Mark Cuban is blaming the wrong people for high drug costs

Trump demands the U.S. pay no more for drugs than other countries … again

Be careful with at

Duchenne breakthrough therapy leaves behind pioneering families

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Wikipedia

Indictment alleges Trump's ex

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

Idaho college killings prosecutors challenge defense's grand jury claims

Pregnancy discrimination could be enabled by AI

Radiology is caught between AI's potential and concern for patients

Radiology is caught between AI's potential and concern for patients

entertainment

focus

focus

focus